Creative Biolabs provides integrated in vivo preclinical study services to help research teams evaluate oncolytic virus candidates from early proof-of-concept through IND-enabling data package planning.
In vivo studies bridge the gap between in vitro validation and clinical translation. For oncolytic virus programs, the central question is not only whether a candidate reduces tumor burden, but also how the virus behaves in a living host: where it localizes, how long it persists, whether it replicates selectively in tumor tissue, how it reshapes antitumor immunity, and whether treatment-associated safety signals remain manageable.
Because oncolytic viruses combine direct tumor cell lysis with immune-mediated antitumor activity, in vivo evaluation requires more than a routine tumor growth study. Creative Biolabs designs study modules around viral tropism, host antiviral immunity, tumor immune microenvironment, administration route, systemic dissemination, safety risks, and the translational purpose of each dataset.
This scope section provides a concise overview of the service framework. Specialized child pages below offer deeper entry points for model selection, efficacy, biodistribution, toxicology, and immunogenicity studies.
| Service Layer | How We Support the Study | Planning Output |
|---|---|---|
| Study strategy and objective setting | Translate the development question into a practical animal study plan, including candidate status, virus platform, target indication, route concept, study stage, and key decision criteria. | Protocol framework, study logic, and decision-oriented endpoint hierarchy. |
| Model and route feasibility planning | Assess whether the proposed tumor model, host background, immune context, administration route, and sample collection plan can answer the intended biological and translational question. | Model-route recommendation and feasibility notes for execution. |
| Efficacy and response evaluation | Design antitumor activity studies that connect treatment schedule, tumor response, candidate comparison, and interpretation of therapeutic relevance. | Proof-of-concept efficacy plan and response interpretation framework. |
| Viral localization and release assessment | Plan biodistribution, persistence, and shedding studies to clarify whether the OV reaches intended sites, remains detectable over time, or appears in non-target matrices. | Sampling matrix, time-course design, and exposure interpretation plan. |
| Immune and mechanism context | Connect tumor response with immune activation, antiviral response, payload activity, or combination-therapy biology when mechanistic interpretation is important. | Mechanism-oriented biomarker and immune profiling plan. |
| Safety and tolerability framework | Build safety monitoring into the study design according to route, dose, repeat dosing, viral platform, replication status, and expected immune activity. | Tolerability monitoring plan and safety interpretation strategy. |
| Integrated data package | Combine results across selected modules so that efficacy, localization, immune context, and safety findings support a clear next-step recommendation. | Integrated report structure, candidate recommendation, and gap analysis. |
This bento-style map uses development decision scenarios rather than FAQ-style questions, so visitors can quickly identify the right child service pathway.
Choose a model strategy according to viral tropism, immune relevance, administration route, tumor indication, and sample collection needs.
Output: model rationaleConfirm tumor response, survival benefit, route feasibility, dose level, and treatment schedule in a relevant animal model.
Output: efficacy evidenceMap viral load, tumor enrichment, off-target tissue exposure, persistence, and clearance patterns after dosing.
Output: tissue mapPlan shedding-related sample types, collection windows, assay approaches, and interpretation for route-specific risk evaluation.
Output: shedding profileCapture tolerability, dose-related observations, pathology, clinical chemistry, hematology, and route-specific safety signals.
Output: safety snapshotCharacterize cytokine response, immune-cell infiltration, tumor immune microenvironment conversion, neutralizing response, and combination rationale.
Output: immune mechanism profileRather than treating animal models as interchangeable platforms, Creative Biolabs helps clients define the biological assumptions, execution constraints, and interpretation limits before study initiation.
Each module can be opened independently to show the key development decision it supports and how the resulting data can be used for go/no-go, optimization, or next-study planning.
Creative Biolabs can support the full in vivo preclinical workflow or provide selected modules according to your available data and development timeline.
Define viral platform, tumor indication, mechanism, administration route, available data, and development objective.
Select model type, treatment arms, dose levels, schedule, endpoints, sample matrices, and statistical approach.
Prepare tumor-bearing animals, confirm eligibility, collect baseline measurements, and randomize groups.
Administer virus or combination regimen and monitor tumor response, clinical signs, body weight, survival, and observations.
Analyze tumor, tissue, blood, body-fluid, immune, molecular, pathology, and safety endpoints.
Deliver graphs, statistics, interpretation, study report, candidate ranking, and next-step recommendations.
Start from a newly constructed OV candidate, a set of engineered variants, a dose/route question, an armed payload program, a combination therapy hypothesis, or preparation for IND-enabling planning.
Deliverables can be configured for proof-of-concept efficacy, model comparison, route and dose optimization, biodistribution and shedding characterization, safety evaluation, immune profiling, or IND-enabling package planning.
Instead of repeating individual study modules, this section describes common program situations where clients need a coordinated animal study strategy.
The project has promising construction or cell-level data, but still needs a focused animal study to confirm whether the candidate is worth expanded development.
Multiple promoters, payloads, attenuation designs, or capsid modifications require a fair comparison under the same model, route, and decision rules.
The team needs to understand whether local, systemic, regional, or site-specific dosing is practical for the tumor location, virus behavior, and safety profile.
The study should show not only tumor response, but also whether the encoded payload, immune pathway, or local tumor microenvironment effect supports the intended design.
The project requires a coordinated monotherapy and combination design that can explain why a partner therapy improves response or overcomes resistance.
Existing results need to be converted into a clear evidence package for internal review, investor communication, collaborator discussion, or later preclinical planning.
Creative Biolabs can refine the study proposal according to the information and materials available at project initiation.
Share viral platform, construct design, replication status, payload, titer information, available in vitro data, prior animal data, formulation, and storage condition.
Provide target tumor indication, preferred administration route, model preference, combination partner, key endpoint priorities, sample requirements, and the next development milestone.
Creative Biolabs combines oncolytic virus biology, tumor model development, immune-oncology evaluation, molecular quantification, and translational study planning in one integrated service framework.
Our team can help clients avoid fragmented study designs by linking efficacy, biodistribution, shedding, immunogenicity, toxicology, and safety endpoints to the same development objective.
Browse answers about model selection, endpoint integration, administration routes, shedding analysis, combination therapy studies, and toxicology planning.
Animal model selection should be based on viral host range, tumor permissivity, immune mechanism, administration route, payload design, target indication, and the main decision the study needs to support. Xenograft models can be efficient for direct oncolysis questions, while syngeneic or humanized models may be more suitable for immune-related endpoints.
Yes, when the protocol is designed carefully. Integrated sampling can reduce duplicated animal use and make the dataset easier to interpret, but treatment groups, time points, matrices, and endpoint priorities should be planned before study initiation.
Biodistribution focuses on where viral material or infectious virus is detected inside tissues and organs, while shedding analysis evaluates whether viral material or infectious virus is released from the host through samples such as urine, feces, saliva, swabs, injection-site material, or other body fluids.
Common options include intratumoral, intravenous, intraperitoneal, intracranial, regional, and other route-specific strategies. Route selection should match the tumor model, intended clinical use, dissemination question, and safety evaluation plan.
Yes. Study arms can be designed to compare oncolytic virus monotherapy with combinations involving immune checkpoint inhibitors, adoptive cell therapy, chemotherapy, radiotherapy, cytokines, cancer vaccines, or other agents, with endpoint panels aligned to the expected mechanism.
Exploratory and toxicology-oriented in vivo studies can identify tolerability signals, endpoint needs, and data gaps before later regulatory-stage work. Formal GLP or IND-enabling toxicology requirements should be planned according to the specific product, route, indication, and regulatory strategy.
Contact Creative Biolabs to discuss your OV candidate, current evidence, and next development decision. Our team can help translate your program goal into a customized animal study strategy with appropriate model, route, sampling, and reporting logic.